Based on the RxPONDER trial (NCT01272037) [13, 14], patients with ER+HER2−, early-stage, lymph node-positive (pN+) breast cancer also derive benefit from the Oncotype Dx assay. This evidence concerns the gene ESR1 and breast cancer.